Literature DB >> 553334

Phenytoin: EEG effects and plasma levels in volunteers.

M Fink, P Irwin, W Sannita, Y Papakostas, M A Green.   

Abstract

The electroencephalographic (EEG) and behavioral effects of oral doses of phenytoin from 100 mg to 1 g in normal male volunteers were measured. The electroencephalogram exhibited decreases in power in the slow frequencies and increases in the fast frequencies, accompanied by an increase in mean frequency. These changes are similar to those seen with psychostimulants. They occurred at average plasma levels of 8 micrograms/ml and above. The time course and the intensity of EEG effects parallel plasma levels. Drug-related EEG changes were bilaterally symmetric. EEG changes at plasma levels of 8--12 micrograms/ml were not associated with behavioral toxic signs. These findings suggest that future psychiatric studies of phenytoin as a psychostimulant should include monitoring for plasma levels, with a minimum of 8 micrograms/ml as a guide to clinical efficacy.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 553334

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  4 in total

1.  EEG and behavioral profile of flutroline (CP-36,584), a novel antipsychotic drug.

Authors:  M Fink; P Irwin
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

2.  Preliminary evaluation of potential anti-epileptic drugs by single dose electrophysiological and pharmacological studies in patients.

Authors:  C D Binnie
Journal:  J Neural Transm       Date:  1988       Impact factor: 3.575

Review 3.  Quantitative Pharmaco-Electroencephalography in Antiepileptic Drug Research.

Authors:  Yvonne Höller; Christoph Helmstaedter; Klaus Lehnertz
Journal:  CNS Drugs       Date:  2018-09       Impact factor: 5.749

4.  Development of antipsychotic medications with novel mechanisms of action based on computational modeling of hippocampal neuropathology.

Authors:  Peter J Siekmeier; David P vanMaanen
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.